Search results
Showing 1 to 15 of 264 results for inflammation
Dupilumab for treating severe asthma with type 2 inflammation (TA751)
Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.
Awaiting development Reference number: GID-TA10198 Expected publication date: TBC
This guideline covers diagnosing and managing gallstone disease in adults. It aims to reduce variation in care by promoting the most effective treatments, and to improve the advice given to people with gallstone disease before and after treatment.
This guideline covers using colonoscopy to check for signs of bowel cancer in people aged 18 and over with ulcerative colitis or Crohn’s disease (types of inflammatory bowel disease) or adenomas (also known as polyps). It aims to prevent cancer and prolong life by offering advice on identifying early bowel cancer in adults most at risk.
This guideline sets out an antimicrobial prescribing strategy for insect and spider bites and stings in adults, young people and children aged 72 hours and over, including those that occurred while travelling outside the UK. It aims to limit antibiotic use and reduce antibiotic resistance.
View recommendations for NG182Show all sections
CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)
In development Reference number: GID-HTE10085 Expected publication date: TBC
This guideline covers the diagnosis and management of diverticular disease in people aged 18 years and over. It aims to improve diagnosis and care and help people get timely information and advice, including advice about symptoms and when to seek help.
This quality standard covers diagnosing and managing gallstones in adults. It also includes managing complications of gallstones, such as an inflamed or infected gallbladder (cholecystitis), blocked and infected bile ducts (cholangitis), and an inflamed pancreas (pancreatitis). It describes high-quality care in priority areas for improvement.
View quality statements for QS104Show all sections
Sections for QS104
- Quality statements
- Quality statement 1: Acute cholecystitis
- Quality statement 2: Urgent endoscopic retrograde cholangiopancreatography within 72 hours
- Quality statement 3: Emergency endoscopic retrograde cholangiopancreatography within 24 hours
- Quality statement 4: Advice to prevent symptoms
- About this quality standard
Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.
This quality standard covers diagnosing and managing spondyloarthritis in adults aged 16 and over. It describes high-quality care in priority areas for improvement.
Evidence-based recommendations on bimekizumab (Bimzelx) for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults.
This asthma pathway signposts recommendations and resources from the British Thoracic Society (BTS), National Institute for Health and Care Excellence (NICE) and Scottish Intercollegiate Guidelines Network (SIGN) on diagnosing, monitoring and managing asthma in adults, young people and children, so you can see what guidance is available all in one place.
Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)
Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults.
Early value assessment (EVA) guidance on CaRi-Heart for predicting cardiac risk in suspected coronary artery disease.
Evidence-based recommendations on intranasal phototherapy for allergic rhinitis in adults. This involves using light to reduce inflammation inside the nose.
View recommendations for HTG473Show all sections